Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults

Martinón-Torres, Federico; Nolan, Terry; Toneatto, Daniela; Banzhoff, Angelika

doi:10.1080/21645515.2019.1627159

Cited by 22 publications

(19 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4CMenB can be co-administered with most of the routinely recommended childhood vaccines. While antibodies waned after priming in infants and children, persistence up to 36 months after various schedules of 4CMenB and robust booster responses indicative of immune memory were reported [ 73 , 78 ]. Studies performed in adolescents and adults established the immunogenicity of 4CMenB after two doses [ 73 ].…”

Section: Meningococcal Protein-based Vaccinesmentioning

confidence: 99%

Vaccines against Meningococcal Diseases

Pizza¹,

Bekkat-Berkani

Rappuoli³

2020

Microorganisms

View full text Add to dashboard Cite

Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W, and Y). Vaccination programs with monovalent meningococcal serogroup C (MenC) conjugate vaccines in Europe have successfully decreased MenC disease and carriage. The use of a monovalent MenA conjugate vaccine in the African meningitis belt has led to a near elimination of MenA disease. Due to the emergence of non-vaccine serogroups, recommendations have gradually shifted, in many countries, from monovalent conjugate vaccines to quadrivalent MenACWY conjugate vaccines to provide broader protection. Recent real-world effectiveness of broad-coverage, protein-based MenB vaccines has been reassuring. Vaccines are also used to control meningococcal outbreaks. Despite major improvements, meningococcal disease remains a global public health concern. Further research into changing epidemiology is needed. Ongoing efforts are being made to develop next-generation, pentavalent vaccines including a MenACWYX conjugate vaccine and a MenACWY conjugate vaccine combined with MenB, which are expected to contribute to the global control of meningitis.

show abstract

Section: Meningococcal Protein-based Vaccinesmentioning

confidence: 99%

Vaccines against Meningococcal Diseases

Pizza¹,

Bekkat-Berkani

Rappuoli³

2020

Microorganisms

View full text Add to dashboard Cite

show abstract

“…In terms of long-term immunogenicity, the primary course is sufficient to achieve a satisfactory immune response within 30 days of vaccination for both infants and adolescents 29,76. A booster dose at 12 months with 4CMenB improved bactericidal responses and facilitated immune persistence in infants until 28 months of age 29.…”

Section: Clinical Studies On Meningococcal B Vaccinesmentioning

confidence: 99%

Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B

Rivero‐Calle

Raguindin²,

Gómez-Rial³

et al. 2019

IDR

Self Cite

View full text Add to dashboard Cite

Invasive meningococcal disease (IMD) is a major public health concern because of its high case fatality, long-term morbidity, and potential to course with outbreaks. IMD caused by Nesseira meningitidis serogroup B has been predominant in different regions of the world like Europe and only recently broadly protective vaccines against B serogroup have become available. Two protein-based vaccines, namely 4CMenB (Bexsero®) and rLP2086 (Trumenba®) are currently licensed for use in different countries against MenB disease. These vaccines came from a novel technology on vaccine design (or antigen selection) using highly specific antigen targets identified through whole-genome sequence analysis. Moreover, it has the potential to confer protection against non-B meningococcus and against other Neisserial species such as gonococcus. Real-world data on the vaccine-use are rapidly accumulating from the UK and other countries which used the vaccine for control of outbreak or as part of routine immunization program, reiterating its safety and efficacy. Additional data on real-life effectiveness, long-term immunity, and eventual herd effects, including estimates on vaccine impact for cost-effectiveness assessment are further needed. Given the predominance of MenB in Europe and other parts of the world, these new vaccines are crucial for the prevention and public health control of the disease, and should be considered.

show abstract

“…With the introduction of reverse vaccinology, some minor highly conserved proteins have been identified based on the analysis of the N. meningitidis serogroup B (NMB) genome, using data from the Molecular Biology Software and Genome Database (GDB). Published data show that a MenB vaccine based on recombinant proteins can elicit a robust bactericidal immune response against a broad range of serogroup B isolates in adults, adolescents, and infants 5. However, the first new vaccine, termed 4CmenB, could not confer protection against all invasive MenB strains.…”

Section: Introductionmentioning

confidence: 99%

Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice

Hou

Yan

Cao

et al. 2019

IJN

View full text Add to dashboard Cite

Purpose The primary goal of the present study was to explore and evaluate the highly conserved Neisserial surface protein A (NspA) molecule, fused with truncated HBV virus-like particles (VLPs), as a candidate vaccine against the virulent Neisseria meningitidis serogroup B (NMB). Methods NspA was inserted into the major immunodominant region of the truncated hepatitis B virus core protein (HBc; amino acids 1–144). The chimeric protein, HBc-N144-NspA, was expressed from a prokaryotic vector and generated HBc-like particles, as determined by transmission electron microscopy. Further, the chimeric protein and control proteins were used to immunize mice and the resulting immune responses evaluated by flow cytometry, enzyme-linked immunosorbent assay, and analysis of serum bactericidal activity (SBA) titer. Results Evaluation of the immunogenicity of the recombinant HBc-N144-NspA protein showed that it elicited the production of high levels of NspA-specific total IgG. The SBA titer of HBc-N144-NspA/F reached 1:16 2 weeks after the last immunization in BALB/c mice, when human serum complement was included in the vaccine. Immunization of HBc-N144-NspA, even without adjuvant, induced high levels of IL-4 and a high IgG1 to IgG2a ratio, confirming induction of an intense Th2 immune response. Levels of IL-17A increased rapidly in mice after the first immunization with HBc-N144-NspA, indicating the potential for this vaccine to induce a mucosal immune response. Meanwhile, the immunization of HBc-N144-NspA without adjuvant induced only mild inflammatory infiltration into the mouse muscle tissue. Conclusion This study demonstrates that modification using HBc renders NspA a candidate vaccine, which can trigger protective immunity against NMB.

show abstract

Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults

Cited by 22 publications

References 48 publications

Vaccines against Meningococcal Diseases

Vaccines against Meningococcal Diseases

<p>Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By <em>Neisseria meningitidis</em> Serogroup B</p>

<p>Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent <em>Neisseria meningitidis</em> serogroup B in BALB/c mice</p>

Contact Info

Product

Resources

About